TGFB1 and neoplasm: Although antibody-fused TGF-β trap fusions are attractive from a manufacturing cost point-of-view, caution should be exercised in their use in terms of treatment timing (i.e., disease stage, tumor type, and its use in combination therapies), given TGF-β‘s dual role as a tumor suppressor and tumor promotor.